Merrill Lynch initiates Speedel coverage at buy

Speedel coverage was initiated by Merrill Lynch analyst Peter Welford at a buy rating and a CHF 175 price target as Merrill Lynch expects product news flow over the next 12 months, particularly on SPP100 for cardiovascular disease, to provide a catalyst for the stock. The company has an attractive late-stage product pipeline, but risks include the potential need for funding by the end of 2006. Shares of the Basel, Switzerland, biopharmaceutical company were unchanged at CHF 141.00 on volume of 3,426 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.